Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40002281
Localisation
Germany
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
31/10/2024
Statut
Classification
1.5°C
Année cible
2032
Statut
Targets set
Classification
1.5°C
Année cible
2045
Overall Net-Zero Target: Evotec SE commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Evotec SE commits to reduce absolute scope 1 and 2 GHG emissions 50.4% by 2032 from a 2021 base year. Evotec SE also commits to increase active annual sourcing of renewable electricity from 25% in 2021 to 100% by 2026, and to continue active annual sourcing of 100% renewable electricity through 2030. Evotec SE commits to reduce scope 3 GHG from purchased goods and services and capital goods 72% per million EUR value added by 2032 from a 2021 base year. Evotec also commits that 80% of its suppliers by emissions covering purchased goods and services and capital goods will have science-based targets by 2027. Long-Term Targets: Evotec SE commits to reduce absolute scope 1 and 2 GHG emissions 95% by 2045 from a 2021 base year. Evotec SE also commits to reduce scope 3 GHG emissions by 97% per million EUR value added within the same timeframe.
Statut
Targets setAnnée cible
2045
Statut
BA1.5 memberDate d'engagement
07/01/2021
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
DE0005664809
LEI
529900F9KI6OYITO9B12
Source : Science Based Targets initiative | Données publiques